Skip to main content

Table 3 Prognostic factors of disease-free survival

From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer

Characteristics5-year DFS (%)Univariate
p-value
Multivariate
p-value
HR
(95% CI)
Age≤40 years (n = 38)85.5%0.0070.0120.301
(0.118–0.767)
> 40 years (n = 46)60.7%
Tumor subtype1)Non-TNBC (n = 54)80.7%0.012< 0.0010.189
(0.079–0.453)
TNBC (n = 30)56.7%
cT stages1–2 (n = 47)77.9%0.0900.0700.442
(0.183–1.068)
3–4 (n = 37)64.8%
cN stages2b or 3b (n = 63)72.1%0.576
3c (n = 21)71.4%
Malignant cells on FNABx of the IMN(−) or unknown (n = 44)73.7%0.610
(+) (n = 40)65.4%
Extent of IMNSingle ICS (n = 37)74.9%0.525
Multiple ICS (n = 47)63.4%
IMN long diameter< 1.0 cm (n = 42)87.9%0.002< 0.0010.157
(0.060–0.412)
≥1.0 cm (n = 42)56.4%
Neoadjuvant chemotherapyPerformed (n = 66)72.1%0.927
Not performed (n = 18)71.1%
Axillary surgeryALND (n = 74)69.5%0.1840.0568.003
(0.947–67.663)
SLNB (n = 10)90.0%
EQD2 of the IMN2)50.0–63.5 Gy (n = 35)65.1%0.1880.0292.491
(1.095–5.663)
63.6–70.4 Gy (n = 49)76.6%
  1. 1)TNBC was defined as tumors that were negative for the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 on immunohistochemical staining of the breast tumor
  2. 2)Radiotherapy dose was calculated using the EQD2 assuming the α/β ratio of 3.5 Gy
  3. Abbreviations: DFS Disease-free survival, TNBC Triple-negative breast cancer, FNABx, fine needle aspiration biopsy, IMN Internal mammary node, ICS Intercostal space, ALND Axillary lymph node dissection, SLNB Sentinel lymph node biopsy; HR Hazard ratio; CI Confidence interval, EQD2 Biologically equivalent dose in 2 Gy fractions